HOME >> BIOLOGY >> NEWS
Can Gleevec help patients with rheumatoid arthritis?

Imatinib mesylate (Gleevec; Novartis) is often the treatment of choice for individuals with either chronic myelogenous leukemia or gastrointestinal stromal tumors. Now, in a study appearing online on September 14 in advance of publication in the October print issue of the Journal of Clinical Investigation, researchers from Stanford University have shown that imatinib can block the development of disease in a mouse model of rheumatoid arthritis (RA), providing hope of a new treatment for RA.

Although there are two documented cases in which individuals taking imatinib to treat their cancer showed clinical improvement in their RA, there had been no study of the effects of imatinib in a mouse pre-clinical model of RA. So, William Robinson and colleagues administered imatinib to mice with an RA-like disease. Imatinib both prevented the onset of disease and the development of established disease. It did this by inhibiting the function of many of the immune cells that contribute to disease in patients with RA. Importantly, imatinib was also shown to inhibit the proliferation of cells taken from the joints of patients with RA. This study indicates that imatinib might provide relief to the many individuals suffering from RA.


'"/>

Contact: Karen Honey
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
14-Sep-2006


Page: 1

Related biology news :

1. When Gleevec is not enough
2. Single genetic assay could help physicians decide when to switch patients from Gleevec to Sutent
3. Drug that battles resistance to leukemia pill Gleevec extremely effective against cancer
4. A broken stress response system can contribute to Gleevec resistance
5. First report of cancer drug Gleevec as new target therapy for pulmonary hypertension
6. Next-era targeted therapy overcoming Gleevecs shortcomings
7. New drug sidesteps Gleevec resistance in human trials
8. Abnormal fat metabolism underlies heart problems in diabetic patients
9. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
10. Aggressive therapy best for certain AML patients
11. Investigating antibiotic use in acute care patients

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Can Gleevec help patients with rheumatoid arthritis

(Date:5/26/2015)... , May 26, 2015 ... announced the addition of the "Saudi Arabia ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... Arabia is projected to grow at ... high growth is attributed to the surging demand ...
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/19/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
(Date:5/27/2015)...  US-Australian drug discovery and development company, Novogen Limited (ASX: ... present at the Brain Tumor Biotech Summit 2015, being held ... 2015. The venue is the Lennox Hill Hospital, East 76 ... The Brain Tumor Biotech Summit brings together the nation,s ... investment community to promote innovative new therapies for brain tumors.  ...
(Date:5/26/2015)... BELLINGHAM, Washington, USA (PRWEB) May 26, 2015 ... a formal partnership with the Max Planck Society ... Extreme and Quantum Photonics. The center will link two ... of photonics, and will be only the third Max ... SPIE, the international society for optics and photonics, ...
(Date:5/26/2015)... HILDEN, Deutschland, May 26, 2015 ... ®   ermöglicht klinischen Laboren ... dazugehöriger Berichte; Vorstellung auf den Konferenzen ClinGen, ... N.V. (NASDAQ: QGEN ; Frankfurt Prime ... QIAGEN Clinical Insight ® (QCI™) bekannt. ...
(Date:5/26/2015)...  Alere Inc. (NYSE: ALR ) (the "Company") announced ... file its Quarterly Report on Form 10-Q for the three ... received a notice from the New York Stock Exchange (the ... NYSE,s continued listing requirements under the timely filing criteria established ... The reason for the delay relates to Company,s ...
Breaking Biology Technology:Novogen to Present at Brain Tumor Biotech Summit 2015 2Novogen to Present at Brain Tumor Biotech Summit 2015 3Novogen to Present at Brain Tumor Biotech Summit 2015 4Novogen to Present at Brain Tumor Biotech Summit 2015 5Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6
Cached News: